Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical leader developing innovative therapies for kidney disease, including FDA-approved Auryxia® and investigational oral HIF inhibitor Vafseo™. This page provides authorized updates on clinical developments, regulatory milestones, and strategic initiatives shaping renal care.
Access Akebia's official press releases covering phase 3 trial results, regulatory submissions, and commercial partnerships with dialysis providers. Investors will find timely updates on financial performance, including earnings calls and SEC filings related to anemia treatment innovations.
Our curated news collection helps stakeholders track progress in HIF biology applications and chronic kidney disease management. Bookmark this page for verified updates on product approvals, research collaborations, and market expansion strategies directly from Akebia Therapeutics.
Akebia Therapeutics® (Nasdaq: AKBA) reported Q1 2021 financial results, showing total revenue of $52.3 million, a decline from $88.5 million in Q1 2020. Collaboration revenue fell to $21.9 million from $59.3 million last year, while net product revenue increased by 4% to $30.4 million. The net loss widened to $69.6 million from $60.7 million. Notably, the NDA for vadadustat was submitted to the FDA, a key milestone for the company. Cash reserves remain strong at $272.8 million, expected to fund operations beyond the anticipated U.S. launch of vadadustat.
On May 4, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to 9 new employees. A total of 197,200 shares were offered, each with an exercise price of $3.19, equal to the stock's closing price on April 30, 2021. The options will vest over four years, with 25% vesting on the first anniversary, and the remainder vesting quarterly. These grants comply with Nasdaq Listing Rule 5635(c)(4), intended to incentivize new hires.
Akebia Therapeutics (Nasdaq: AKBA) announced the publication of its Phase 3 clinical program results for vadadustat in the New England Journal of Medicine. The program evaluated vadadustat's effectiveness in treating anemia due to chronic kidney disease (CKD) in patients on and not on dialysis. A New Drug Application (NDA) was submitted to the FDA for vadadustat recently. The program demonstrated that vadadustat is noninferior to darbepoetin alfa for cardiovascular safety in dialysis patients, but did not meet the same for non-dialysis patients.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its financial results for Q1 2021 on May 10, 2021, prior to market opening. The results will be followed by a conference call at 9:00 a.m. ET to discuss financial outcomes and business highlights. Interested parties can join the call by dialing specific numbers or through a live webcast available on the company's website.
The replay will be accessible until May 16, 2021. Founded in 2007 and based in Cambridge, MA, Akebia focuses on developing therapeutics for kidney disease.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced that CEO John P. Butler will present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 1:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page, with a replay accessible for 30 days post-conference. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia aims to improve the lives of those affected by kidney disease.
On April 2, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to 19 new employees totaling 131,000 shares to enhance recruitment efforts. These options have an exercise price of $3.38, the same as the stock's closing price on the grant date. Each option vests over four years, with 25% vesting after one year and the remainder quarterly, contingent on continued employment. The options adhere to Nasdaq Listing Rule 5635(c)(4) as part of the company's Inducement Award Program.
Akebia Therapeutics (Nasdaq: AKBA) announced the submission of a New Drug Application (NDA) for vadadustat, aimed at treating anemia due to chronic kidney disease (CKD) in adult patients, both on and off dialysis. The NDA encompasses data from over 8,000 patients across 36 clinical trials. The FDA has a 60-day window to assess if the NDA is acceptable for review. Further, Akebia is collaborating with Otsuka Pharmaceutical for a Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) later this year.
Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the virtual National Kidney Foundation 2021 Spring Clinical Meetings from April 6-10, 2021. The company will present new data including a poster on a Phase 1 study regarding the drug vadadustat, an investigational treatment for anemia due to chronic kidney disease (CKD). Vadadustat's global Phase 3 program is complete, although it is only approved in Japan. Akebia will also support an educational session on CKD-related anemia treatments.
Akebia Therapeutics (Nasdaq: AKBA) announced that its partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for Riona® Tablets (ferric citrate hydrate) to treat iron deficiency anemia (IDA) in adult patients in Japan. This approval follows the original marketing authorization obtained in 2014 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. Akebia's Auryxia® has similar indications in the U.S.
